Ghasempour Dabaghi, G., Rabiee Rad, M., Mohammad-Zamani, M., Karimi Shervedani, A., Bahrami-Samani, F., & Heshmat-Ghahdarijani, K
Key Insight: The contribution to total spend on GLP-1s for members with obesity without a diabetes diagnosis has grown significantly, now constituting almost 16.5% of spend on these drugs compared to 11% in 2022 and just 4% in 2020
How it works: In theory, TB-500 regulates actin, a protein that helps healing cells migrate to injury sites
NR or NMN) or pharmacological activation of sirtuin pathways restores autophagy activity, enhancing both lipophagy and mitophagy
Appetite and Satiety Effects The theoretical appeal of combining these two is additive appetite suppression
doi: 10.1155/2020/5854919 133 XuKYXiaGHLuJQChenMXZhenXWangSet al